Rivaroxaban

利伐沙班

Report date: 2026/05/06 20:02:28
NMEFirst In Class

Base Information

Drug NameRivaroxaban
Drug Alias Name拉伐沙班rivaroxabanum立伐沙班Xarelto拜瑞妥 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFactor Xa inhibitors
TargetsCoagulation factor X
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeBreast Milk Expression +[52] 
Global Approved IndicationsIschemic StrokeVenous ThrombosisVenous Thromboembolism +[7] 
Approved Indications in ChinaVenous ThrombosisEmbolism
Original Approved Country/TerritoryCanada
Original Approved Date2008/09/15
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[88] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AGJohnson & Johnson Pharmaceutical Research & Development LLC
China Registration ClassN/A

Develop Information

Active CompaniesRawalpindi Institute Of CardiologyCanadian Institutes Of Health Research (Cihr)Science Valley Research Institute +[18] 
Inactive CompaniesJanssen R&D LlcBayer Pharma AgGenuine Research Center, Egypt +[21] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeBreast Milk Expression +[30] 
Inactive IndicationsPostoperative ComplicationsIntraoperative ComplicationsHemorrhage +[22] 

Other Information

ATC CodeB01AF01
Related LinksWikipediaDrugBankKEGG